Second-generation, atypical antipsychotic, employed in the treatment of schizophrenia, schizoaffective disorder, mixed and manic states characterizing bipolar disorder, and irritability in autistic children. Approved in 1993 by the U.S. F.D.A. Under the trade name Risperdal.